NOX-E36

TME Pharma AG · Phase 2 active Small molecule

At a glance

Generic name	NOX-E36
Sponsor	TME Pharma AG
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria (PHASE2)
NOX-E36 Multiple Ascending Dose Study in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus (PHASE1, PHASE2)
NOX-E36 First-in-Human (FIH) Study (PHASE1)
A Phase I Clinical Trial to Evaluate the Effect of Renal Impairment on Pharmacokinetics of NOX-E36 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NOX-E36 CI brief — competitive landscape report
NOX-E36 updates RSS · CI watch RSS
TME Pharma AG portfolio CI